Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHIELD: Trastuzumab, Serplulimab, and Chemotherapy in HER2+ Advanced Biliary Tract Cancer or Urothelial Carcinoma
NCT07506057Phase 2Recruiting
- Start
- Jul 2025
- Primary completion
- Jul 2027
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of serplulimab, trastuzumab in biliary tract cancer (BTC), urothelial carcinoma (UC). Started Jul 2025; status: recruiting.
02
Drugs
serplulimabtrastuzumab
03
Conditions
biliary tract cancer (BTC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT07506057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07506057.